U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H27N5O4S
Molecular Weight 445.535
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLIPIZIDE

SMILES

CC1=NC=C(N=C1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3

InChI

InChIKey=ZJJXGWJIGJFDTL-UHFFFAOYSA-N
InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)

HIDE SMILES / InChI
Molecular Formula C21H27N5O4S
Molecular Weight 445.535
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/glipizide.html

Glipizide, a second-generation sulfonylurea, is used with diet to lower blood glucose in patients with diabetes mellitus type II. The primary mode of action of glipizide in experimental animals appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus dependent on functioning beta cells in the pancreatic islets. In humans glipizide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. In man, stimulation of insulin secretion by glipizide in response to a meal is undoubtedly of major importance. Fasting insulin levels are not elevated even on long-term glipizide administration, but the postprandial insulin response continues to be enhanced after at least 6 months of treatment. Some patients fail to respond initially, or gradually lose their responsiveness to sulfonylurea drugs, including glipizide. Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. Glipizide is used as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory. Glipizide is marketed by Pfizer under the brand name Glucotrol in the USA, where Pfizer sells Glucotrol in doses of 5 and 10 milligrams and Glucotrol XL (an extended release form of glipizide) in doses of 2.5, 5, and 10 milligrams. Other companies also market glipizide, most commonly extended release tablets of 5 and 10 milligrams.

Originator

Ambrogi
1
Curator's Comment: first described by Ambrogi in 1971

Approval Year

1984
110
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
GLUCOTROL

Approved Use

GLUCOTROL is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Launch Date

1984
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
465 ng/mL
EXPERIMENT
https://www.ajol.info/index.php/tjpr/article/viewFile/66555/54281
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLIPIZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
523 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/16509763
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLIPIZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1878 ng × h/mL
EXPERIMENT
https://www.ajol.info/index.php/tjpr/article/viewFile/66555/54281
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLIPIZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1897 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/16509763
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLIPIZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
EXPERIMENT
https://www.ajol.info/index.php/tjpr/article/viewFile/66555/54281
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLIPIZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.65 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/16509763
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLIPIZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1.5%
DRUG LABEL
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/1af56e54-3db7-4b15-bf65-dfaf0eacb515/spl-doc?hl=glipizide
GLIPIZIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
375 mg single, oral
Overdose
Dose: 375 mg
Route: oral
Route: single
Dose: 375 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/16794105
healthy, 15
Health Status: healthy
Age Group: 15
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16794105
Disc. AE: Hypoglycaemia...
AEs leading to
discontinuation/dose reduction:
Hypoglycaemia
Sources:
https://pubmed.ncbi.nlm.nih.gov/16794105
1 g single, oral
Overdose
Dose: 1 g
Route: oral
Route: single
Dose: 1 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/16909651
unhealthy, 55
Health Status: unhealthy
Age Group: 55
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/16909651
Disc. AE: Hypoglycaemic encephalopathy...
AEs leading to
discontinuation/dose reduction:
Hypoglycaemic encephalopathy (grade 5)
Sources:
https://pubmed.ncbi.nlm.nih.gov/16909651
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17300595
unhealthy, 56.6 (9.8)
Health Status: unhealthy
Age Group: 56.6 (9.8)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17300595
Disc. AE: Myocardial infarction, Abortion spontaneous...
AEs leading to
discontinuation/dose reduction:
Myocardial infarction (serious, 0.17%)
Abortion spontaneous (serious, 0.17%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/17300595
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21816980
unhealthy, >/=18 years
Health Status: unhealthy
Age Group: >/=18 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21816980
Disc. AE: Hypoglycemia, Pyelonephritis...
AEs leading to
discontinuation/dose reduction:
Hypoglycemia (0.7%)
Pyelonephritis (0.25%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21816980
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017783s021lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017783s021lbl.pdf
Disc. AE: Cardiovascular disorder NOS...
AEs leading to
discontinuation/dose reduction:
Cardiovascular disorder NOS (grade 5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017783s021lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Hypoglycaemia Disc. AE
375 mg single, oral
Overdose
Dose: 375 mg
Route: oral
Route: single
Dose: 375 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/16794105
healthy, 15
Health Status: healthy
Age Group: 15
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16794105
Hypoglycaemic encephalopathy grade 5
Disc. AE
1 g single, oral
Overdose
Dose: 1 g
Route: oral
Route: single
Dose: 1 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/16909651
unhealthy, 55
Health Status: unhealthy
Age Group: 55
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/16909651
Abortion spontaneous serious, 0.17%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17300595
unhealthy, 56.6 (9.8)
Health Status: unhealthy
Age Group: 56.6 (9.8)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17300595
Myocardial infarction serious, 0.17%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17300595
unhealthy, 56.6 (9.8)
Health Status: unhealthy
Age Group: 56.6 (9.8)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17300595
Pyelonephritis 0.25%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21816980
unhealthy, >/=18 years
Health Status: unhealthy
Age Group: >/=18 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21816980
Hypoglycemia 0.7%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21816980
unhealthy, >/=18 years
Health Status: unhealthy
Age Group: >/=18 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21816980
Cardiovascular disorder NOS grade 5
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017783s021lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017783s021lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1193

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C19
1119
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C19
1119
 yes
no (pharmacogenomic study)
Comment: there were detectable differences between CYP2C19 EMs and PMs in the pharmacokinetics and pharmacodynamics of glipizide, but none of these differences were statistically significant
CYP2C9
1193
 yes
weak (co-administration study)
Comment: rifampin decreased the AUC(0-infinity) of glipizide by 22% (P <.05) and shortened its half-life from 3.0 to 1.9 hours (P =.01); pharmacogenomic studies also performed: CYP2C9 polymorphism significantly influences the pharmacokinetics and pharmacodynamics of glipizide, which needs to be considered in clinical practice
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:5384
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5384
ChemicalBook
CB9185001
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9185001
eMolecules
27520373
https://www.emolecules.com/cgi-bin/more?vid=27520373
eMolecules
496510
https://www.emolecules.com/cgi-bin/more?vid=496510
MolPort
MolPort-002-885-830
https://www.molport.com/shop/molecule-link/MolPort-002-885-830
Selleck Chemicals
Glipizide(Glucotrol)
http://www.selleckchem.com/products/Glipizide(Glucotrol).html
ZINC
ZINC000000537795
http://zinc15.docking.org/substances/ZINC000000537795
PubMed

PubMed

TitleDatePubMed
Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview.
2004-12
The association of patient trust and self-care among patients with diabetes mellitus.
2004-11-16
Detection of anti-diabetics in equine plasma and urine by liquid chromatography-tandem mass spectrometry.
2004-11-05
Tempol augments angiotensin II-induced AT2 receptor-mediated relaxation in diabetic rat thoracic aorta.
2004-11
Emphysematous cystitis: an unusual disease of the Genito-Urinary system suspected on imaging.
2004-10-05
Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia.
2004-09
Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing.
2004-08
Cost-effective management of hyperglycemia in patients with type 2 diabetes using oral agents.
2004-07
ppt level detection of samarium(III) with a coated graphite sensor based on an antibiotic.
2004-07
Prolonged hypoglycaemia secondary to extended-release form glipizide.
2004-07
Idiosyncratic toxicity associated with potentiated sulfonamides in the dog.
2004-06
Effects of glipizide GITS and glibenclamide on metabolic control, hepatic glucose production, and insulin secretion in patients with type 2 diabetes.
2004-05-11
Metformin-associated respiratory alkalosis.
2004-05-11
Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride.
2004-05
Development and evaluation of osmotically controlled oral drug delivery system of glipizide.
2004-05
Beneficial metabolic effects of chronic glipizide in obese African Americans with impaired glucose tolerance: implications for primary prevention of type 2 diabetes.
2004-04
Simultaneous determination of glipizide and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry.
2004-03-05
Basal nitric oxide production contributes to membrane potential and vasotone regulation of guinea pig in vitro spiral modiolar artery.
2004-03
Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor.
2004-02
The role of sulphonylureas in the management of type 2 diabetes mellitus.
2004
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
2004
Effect of some penetration enhancers on the permeation of glibenclamide and glipizide through mouse skin.
2003-12
Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets.
2003-11-14
Weight uniformity of split tablets required by a Veterans Affairs policy.
2003-11-14
Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis.
2003-11
Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
2003-11
Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus.
2003-11
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.
2003-10
Managing hemorrhagic shock: fluids on the way out--drugs on the way in?
2003-10
Parenteral administration of glipizide sodium salt, an inhibitor of adenosine triphosphate-sensitive potassium channels, prolongs short-term survival after severe controlled hemorrhage in rats.
2003-10
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington's disease.
2003-08
K(ATP) channels and pancreatic islet blood flow in anesthetized rats: increased blood flow induced by potassium channel openers.
2003-08
Performance liquid chromatographic analysis of glipizide: application to in vitro and in vivo studies.
2003-07
Glipizide treatment with short-term alcohol abuse resulting in subfulminant hepatic failure.
2003-07
Modification of cardiovascular response of posterior hypothalamic adenosine A(2) receptor stimulation by adenylate cylase, guanylate cyclase and by K(ATP) channel blockade in anesthetized rats.
2003-06-19
Combination agents for diabetes.
2003-06
Insulin secretagogues, but not glucose, stimulate an increase in [Ca2+]i in the fetal human and porcine beta-cell.
2003-06
Small amounts of some drugs can be toxic to young children: one pill or one swallow can require aggressive treatment.
2003-06
Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001.
2003-06
Treatment of feline diabetes mellitus using an alpha-glucosidase inhibitor and a low-carbohydrate diet.
2003-06
Effects of sulfonylurea hypoglycemic agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure.
2003-05
Metabolic effects of chronic glipizide gastrointestinal therapeutic system on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant, first-degree relatives of African American patients with type 2 diabetes: new insights on mechanisms of action.
2003-05
Light and scanning electron microscopic evaluation of Glyde File Prep in smear layer removal.
2003-05
[Oral antidiabetic therapy and cardiovascular complications: theoretical problem or clinical evidence?].
2003-04-06
[Differences between oral antidiabetics].
2003-03-20
Barriers to self-monitoring of blood glucose among adults with diabetes in an HMO: a cross sectional study.
2003-03-19
Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
2003-03
Design and in vitro and in vivo evaluation of mucoadhesive microcapsules of glipizide for oral controlled release: a technical note.
2003
Presentation and 5-year follow-up of type 2 diabetes mellitus in African-American and Caribbean-Hispanic adolescents.
2003
Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
2003
Patents

Patents

JP2008510795A
76
JP4633329B2
2

Sample Use Guides

In Vivo Use Guide
Initial dose: 5 mg orally once a day, 30 minutes before breakfast Maintenance dose: Up to 40 mg in divided doses 30 minutes before a meal of adequate caloric content. Doses may be increased in intervals of 2.5 to 5 mg a day according to blood glucose response. Maximum single dose: 15 mg Maximum daily dose: 40 mg
Route of Administration: Oral
In Vitro Use Guide
Glipizide (100 uM) increased PPARγ transcriptional activity in Cos7 cells
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:55:44 GMT 2025
Edited
by admin
on Mon Mar 31 17:55:44 GMT 2025
Record UNII
X7WDT95N5C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLIPIZIDE
EP   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
METAGLIP COMPONENT GLIPIZIDE
Preferred Name English
1-CYCLOHEXYL-3-((P-(2-(5-METHYLPYRAZINECARBOXAMIDO)ETHYL)PHENYL)SULFONYL)UREA
Common Name English
GLIPIZIDE [USP MONOGRAPH]
Common Name English
GLIPIZIDE [JAN]
Common Name English
GLIPIZIDE [USAN]
Common Name English
GLIPIZIDE [VANDF]
Common Name English
K-4024
Code English
K 4024
Code English
GLIPIZIDE [USP-RS]
Common Name English
GLUCOTROL
Brand Name English
CP-28720
Code English
GLIPIZIDE SLOW RELEASE
Common Name English
GLIPIZIDE [EP MONOGRAPH]
Common Name English
GLIPIZIDE [MART.]
Common Name English
Glipizide [WHO-DD]
Common Name English
glipizide [INN]
Common Name English
GLIPIZIDE [ORANGE BOOK]
Common Name English
PYRAZINECARBOXAMIDE, N-(2-(4-((((CYCLOHEXYLAMINO)CARBONYL)AMINO)SULFONYL)PHENYL)ETHYL)-5-METHYL-
Systematic Name English
GLIPIZIDE [MI]
Common Name English
NSC-759120
Code English
CP-28,720
Code English
Classification Tree Code System Code
LIVERTOX 460
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
WHO-VATC QA10BB07
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
NDF-RT N0000008054
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
WHO-ATC A10BB07
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
NDF-RT N0000008054
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
NDF-RT N0000175608
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
NDF-RT N0000008054
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
NCI_THESAURUS C97936
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
Code System Code Type Description
CAS
29094-61-9
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
RS_ITEM_NUM
1292507
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
PUBCHEM
3478
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
CHEBI
5384
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
FDA UNII
X7WDT95N5C
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
NCI_THESAURUS
C29074
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
DAILYMED
X7WDT95N5C
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
ChEMBL
CHEMBL1073
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
DRUG BANK
DB01067
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
DRUG CENTRAL
1301
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
NSC
759120
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
MERCK INDEX
m5747
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY Merck Index
INN
3090
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
MESH
D005913
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
IUPHAR
6821
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
WIKIPEDIA
Glipizide
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
RXCUI
4821
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY RxNorm
ECHA (EC/EINECS)
249-427-6
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
EVMPD
SUB07927MIG
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
SMS_ID
100000090337
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
LACTMED
Glipizide
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
EPA CompTox
DTXSID0040676
Created by admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of GLIPIZIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
ATP-BINDING CASSETTE SUB-FAMILY C MEMBER 8
TARGET -> INHIBITOR
Sulfonylureas bind to and close ATP-sensitive K+ (KATP) channels on the cell membrane of pancreatic beta cells, which depolarizes the cell by preventing potassium from exiting. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of mature insulin.
Structure of GLIPIZIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
Structure of N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]acetamide
METABOLITE LESS ACTIVE -> PARENT
URINE
Structure of TRANS-4'-HYDROXYGLIPIZIDE
METABOLITE LESS ACTIVE -> PARENT
Structure of CIS-3'-GLIPIZIDE
METABOLITE LESS ACTIVE -> PARENT
Related Record Type Details
Structure of 4-(2-((CYCLOHEXYLCARBAMOYL)AMINO)ETHYL)BENZENESULFONAMIDE
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 5-METHYL-N-(2-(4-SULFAMOYLPHENYL)ETHYL)PYRAZINE-2-CARBOXAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYL ((4-(2-(((5-METHYLPYRAZIN-2-YL)CARBONYL)AMINO)ETHYL)PHENYL)SULFONYL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Ethyl N-[[4-[2-[[(5-methyl-2-pyrazinyl)carbonyl]amino]ethyl]phenyl]sulfonyl]carbamate
IMPURITY -> PARENT
Structure of N-(CYCLOHEXYLCARBAMOYL)-4-(2-((CYCLOHEXYLCARBAMOYL)AMINO)ETHYL)BENZENESULFONAMIDE
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 2.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6-METHYL-N-(2-(4-SULFAMOYLPHENYL)ETHYL)PYRAZINE-2-CARBOXAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ETHYL (2-(4-((CYCLOHEXYLCARBAMOYL)SULFAMOYL)PHENYL)ETHYL)CARBAMATE
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ETHYL (2-(4-SULFAMOYLPHENYL)ETHYL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CYCLOHEXYLAMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
EP
Related Record Type Details
Structure of GLIPIZIDE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966